The Campbell's Company (CPB)
NASDAQ: CPB · Real-Time Price · USD
32.69
+0.06 (0.18%)
At close: Aug 6, 2025, 4:00 PM
32.61
-0.08 (-0.24%)
After-hours: Aug 6, 2025, 7:59 PM EDT
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Sage Therapeutics stock have a consensus rating of "Hold" and an average price target of $38.94, which forecasts a 19.12% increase in the stock price over the next year. The lowest target is $30 and the highest is $59.
Price Target: $38.94 (+19.12%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sage Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 7 | 9 | 9 | 10 | 9 | 9 |
| Sell | 1 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 2 | 1 | 2 | 2 | 2 | 2 |
| Total | 15 | 16 | 17 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold Maintains $38 → $34 | Hold | Maintains | $38 → $34 | +4.01% | Jul 29, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $41 → $35 | Buy | Maintains | $41 → $35 | +7.07% | Jul 15, 2025 |
| Barclays | Barclays | Sell Maintains $35 → $30 | Sell | Maintains | $35 → $30 | -8.23% | Jul 14, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $34 → $32 | Hold | Maintains | $34 → $32 | -2.11% | Jul 9, 2025 |
| DA Davidson | DA Davidson | Hold Maintains $39 → $34 | Hold | Maintains | $39 → $34 | +4.01% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
10.38B
from 9.64B
Increased by 7.70%
Revenue Next Year
10.17B
from 10.38B
Decreased by -1.99%
EPS This Year
2.96
from 1.89
Increased by 56.44%
EPS Next Year
2.88
from 2.96
Decreased by -2.46%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.9B | 11.1B | 11.4B | |||
| Avg | 10.4B | 10.2B | 10.3B | |||
| Low | 10.0B | 9.6B | 9.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 12.9% | 7.2% | 11.7% | |||
| Avg | 7.7% | -2.0% | 1.4% | |||
| Low | 4.0% | -7.1% | -4.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.12 | 3.55 | 3.92 | |||
| Avg | 2.96 | 2.88 | 3.09 | |||
| Low | 2.84 | 2.60 | 2.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 65.0% | 20.0% | 35.8% | |||
| Avg | 56.4% | -2.5% | 7.1% | |||
| Low | 50.4% | -12.2% | -2.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.